HIV Prevention by Oral Preexposure Prophylaxis
Open Access
- 6 December 2011
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 2 (3), a007419
- https://doi.org/10.1101/cshperspect.a007419
Abstract
The impressive advances in antiretroviral (ARV) therapy of chronic human immunodeficiency virus (HIV) infections during the last decade and the availability of potent ARV drugs have fueled interest in using chemoprophylaxis as a novel HIV prevention strategy. Preexposure prophylaxis (PrEP) refers to the use of ARV drugs in HIV-negative persons to prevent HIV infection. The rationale for PrEP builds on the success of ARV prophylaxis in preventing mother-to-child transmission of HIV and on a large body of animal studies that show the efficacy of PrEP against mucosal and parenteral infection. We focus on oral administration of ARV drugs for prevention of HIV infection. Identifying an effective prophylactic pill that individuals can take outside the setting of sexual intercourse precludes the necessity to disclose such use to their partners, thereby empowering those who might not be in a position to negotiate with their partners. Several human clinical trials evaluating the efficacy of daily regimens of the HIV reverse-transcriptase (RT) inhibitors tenofovir disoproxil fumarate (TDF) or Truvada (TDF and emtricitabine [FTC]) are under way among high-risk populations. The results of one trial among men who have sex with men showed that daily Truvada was safe and effective, providing the first support for oral PrEP as a prevention strategy. Here we outline the preclinical and clinical research on oral PrEP, pharmacologic considerations, and future directions and challenges.Keywords
This publication has 41 references indexed in Scilit:
- Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative MenThe Journal of Infectious Diseases, 2011
- Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.2011
- Pharmacologic Opportunities for HIV PreventionClinical Pharmacology & Therapeutics, 2010
- Genetic and antigenic features of the transmitted virusCurrent Opinion in HIV and AIDS, 2009
- Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences, 2008
- Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitorNature Medicine, 2005
- CD8+T-Lymphocyte Response to Major Immunodominant Epitopes after Vaginal Exposure to Simian Immunodeficiency Virus: Too Late and Too LittleJournal of Virology, 2005
- Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal TractThe Journal of Experimental Medicine, 2004
- Early establishment of a pool of latently infected, resting CD4 + T cells during primary HIV-1 infectionProceedings of the National Academy of Sciences, 1998